Cutoff: 13 October 2026. Consensus supports discovery and checks of specific source aspects; it is not a primary study, a full-paper audit or a causal probability meter.
The original Welsh body distinguishes eligibility from receipt:3.5points is the fuzzy CACE receipt estimate. It uses a local complier counterfactual-risk construction and not a simple division of the overall control risk. Diagnosis sources and lack of primary competing-death adjustment are explicit. Original PMID40175543. Access: full_text_partial.
Selected original Methods/Results confirm the eligibility estimand, uptake from a separate CHSS survey, primary27.4point first stage with lowerCI0.0 and secondary13.9point interval crossing zero. Women-significant/men-nonsignificant has interactionP=.218; this cannot establish a verified sex boundary. Original PMID41579903. Access: full_text_partial.
The original reports17%increase in diagnosis-free time, with164days among participants subsequently diagnosed, not17%relative risk reduction in all recipients. Calendar transition and active vaccine matching remain observational limitations. Original PMID39053634. Access: abstract_metadata.
The original new quantitative secondary analysis reports18%Wales,177%Australia and84%/111%Canada under its published-estimate scaling. These are analytical estimates rather than new vaccine trials. Their denominator/complier-risk assumptions require reconciliation with the Welsh local CACE method; provider strength labels do not adjudicate the critique. Original PMID42754179. Access: abstract_metadata.
The original reports an association in a clone-censor-weight emulation, with negative controls suggesting residual confounding. Only1.73%received vaccine and87%of these did so after discharge; wording is qualified to association rather than proven lowering. Original PMID42296498. Access: abstract_metadata.
The original is a matched observational comparison with no significant product difference. Nonsignificance is not equivalence, and sharing an adjuvant is not a randomized adjuvant-versus-virus dissociation; the mechanism remains a hypothesis. Original PMID40562756. Access: abstract_metadata.
The original UK cohort reports no increased dementia after overt HZ, no dementia-or-death association, and no antiviral prescription variation. This important challenge is retained alongside positive registry studies and does not itself exclude subclinical viral effects. Original PMID35170873. Access: abstract_metadata.
The original326-village randomized care programme significantly lowers all-cause dementia over48months. This genuine clinical prevention positive is preserved for its exact package, alongside SPRINT dementia-null/MCI-positive and aspirin/HYVET nulls; it neither validates nor refutes vaccination. Original PMID40258956. Access: abstract_metadata.
The original medRxiv repository abstract was independently read: Hamilton etal2026 doi10.64898/2026.07.20.26358345v1 is explicitly unreviewed. It reports hospital-dementia eligibility RD−.06points,CI−.40to.27,P=.72, including Welsh ascertainment comparisons. It is retained as a separate non-counted preprint challenge, with no invented original Methods reading or inclusion among53peer-reviewed reports. Original PMID40175543. Access: full_text_partial.
Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.